



## Extension Seminar in Cardiology

### Program

*This seminar will be delivered by a combination of a self-paced learning package followed by a live one-day seminar*

### Self-paced learning package available from mid-May 2023

Topic and presenter	Learning objectives
<p><b>Chronic coronary artery disease</b></p> <p><b>Dr Derk Pol</b>, <i>General Cardiologist and Interventional Fellow, MonashHeart &amp; Latrobe Regional Hospital, Monash University Lecturer/Tutor</i></p>	<ul style="list-style-type: none"> <li>• Differentiate between the pathophysiology of acute coronary artery stenosis and chronic stenosis</li> <li>• Differentiate between interventional approaches to management of chronic artery disease and acute coronary syndrome</li> <li>• Discuss the evidence behind the use of anti-thrombotic therapy in the management of chronic coronary artery disease</li> <li>• Discuss the evidence behind anti-anginal and anti-inflammatory therapies in the management of chronic coronary artery disease</li> <li>• Develop approaches in appraising the medication management of patients with chronic coronary artery disease to maximise clinical outcomes</li> </ul>
<p><b>Diabetes and heart disease</b></p> <p><b>Sarah Hitchen</b>, <i>Senior Pharmacist, Endocrinology and Respiratory - Fiona Stanley Hospital, South Metropolitan Health Service, Perth, WA</i></p>	<ul style="list-style-type: none"> <li>• Identify where to access local and international guidelines and treatment algorithms for managing type two diabetes mellitus (T2DM)</li> <li>• Apply these to clinical scenarios involving patients with a history of cardiovascular disease.</li> <li>• State the outcomes of key clinical trials leading to SGLT2 inhibitors and glucagon like peptide 1 (GLP1) receptor agonists being favoured to treat patients with T2DM with a history of cardiovascular disease.</li> <li>• Identify practical considerations (dosing, adverse effects, monitoring, precautions) when using SGLT2 inhibitors and GLP 1 receptor agonists.</li> <li>• Consider current Australian Pharmaceutical Benefits Scheme requirements for these agents.</li> <li>• Develop ideas for novel pharmacist roles in medication optimisation in patients with T2DM and cardiac disease.</li> </ul>
<p><b>Pulmonary hypertension</b></p> <p><b>Cassie Potts</b>, <i>Senior Pharmacist – Cardiology, Flinders Medical Centre, Adelaide, SA</i></p> <p><b>Avril Derwent</b>, <i>Clinical Nurse, Flinders Medical Centre, Adelaide, SA</i></p>	<ul style="list-style-type: none"> <li>• Outline the pathophysiology of pulmonary hypertension (PH) and the potential treatment pathways</li> <li>• Describe the classification of pulmonary hypertension and implications for treatment</li> <li>• Describe the haemodynamic parameters required to accurately interpret PBS criteria for common PH drug therapies</li> <li>• Identify dosing, common adverse effects, monitoring requirements and supportive care associated with PH medications</li> <li>• Outline the place of PH medications in potential treatment pathways</li> </ul>

<p><b>Statistics</b></p> <p><b>Adam Livori</b>, <i>Team Leader - Medical Specialties and Ambulatory Care, Grampians Health; PhD Candidate Centre for Medicine Use and Safety, Monash University, Ballarat, Vic</i></p>	<ul style="list-style-type: none"> <li>• Describe the principles behind what randomisation provides in clinical trials</li> <li>• Outline a-priori power calculations and how this impacts the outcome of trials</li> <li>• Describe the use of p-value, relative risk, hazard ratio, confidence interval and what it represents when applying trial data to practice</li> <li>• Describe the rationale behind the use of composite outcomes (MACE) in cardiology trials</li> <li>• Describe how the use of registries is changing the way cardiovascular research is conducted</li> <li>• Describe the relevant conventions in cardiology trials with respect to cardiovascular events, bleeding, thrombosis</li> </ul>
<p><b>Implanted cardiac devices</b></p> <p><b>Garth Birdsey</b>, <i>Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic</i></p>	<ul style="list-style-type: none"> <li>• Outline reasons to pace the heart</li> <li>• Differentiate between defibrillators and pacemakers</li> <li>• Explain how patients are prepared for device implantation</li> <li>• Describe the implications of device selection on therapeutic choices</li> </ul>



## Extension Seminar in Cardiology

Preliminary program

Live virtual seminar

All times listed are in AEST

**Saturday 24 June 2023**

Time (AEST)	Session
0910-0920	Online login available
0920-0930	Welcome, introduction, housekeeping Adam Livori, <i>Seminar Lead</i>
0930-1015	Review of self-paced learning package content with open Q&A Adam Livori
1015-1145	Case session 1: Chronic CAD and diabetes Led by Karl McDermott Tutor team: Adam Livori, Karl Winckel, Hannah Doody
1145-1205	Break
1205-1335	Case session 2: Pulmonary arterial hypertension Led by Adam Livori Tutor team: Karl McDermott, Hannah Doody, Karl Winckel
1335-1420	Cardio-Socratic forum Led by Adam Livori Tutor team: Karl McDermott, Hannah Doody, Karl Winckel
1420-1440	Break
1440-1610	Case session 3: Devices Led by Adam Livori Tutor team: Karl McDermott, Hannah Doody, Karl Winckel
1610-1615	Summary and close
1615	Close of live virtual seminar

*Please note: presentation recordings from the live virtual seminar will not be available.*